Loading patent…
AssigneeSanofi
InventorsCarsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
Estimating the term…
The present invention relates to a peptide or peptide complex binding to α2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting α2 integrin and a screening method.
Peptide or peptide complex, preferably isolated monoclonal antibody or antigen binding fragment thereof, wherein said peptide or peptide complex, antibody or fragment specifically binds to the I-domain of a human α2-integrin, said antibody or fragment comprising a heavy chain variable region (VH) domain and a light chain variable region (VL) domain, wherein said antibody or fragment cross-reacts with a non-human primate α2-integrin but does not cross-react with a non-primate α2-integrin.
Peptide or peptide complex, preferably isolated monoclonal antibody or antigen binding fragment thereof, wherein said peptide or peptide complex, antibody or fragment specifically binds to the I-domain of a human α2-integrin, said antibody comprising a heavy chain variable region (VH) domain and a light chain variable region (VL) domain, wherein said antibody or fragment competes with a reference antibody for binding to the epitope of the reference antibody, said reference antibody comprising a light chain encoded by the plasmid as deposited with the DSMZ under accession No. DSM 23944 and a heavy chain encoded by either (i) the plasmid as deposited with the DSMZ under accession DSM 23946 or (ii) the plasmid as deposited with the DSMZ under accession No. DSM 23945.
Peptide or peptide complex preferably isolated monoclonal antibody or antigen binding fragment thereof, comprising one or more of the following components a to f:
The Peptide or peptide complex according to any of the previous claims, said heavy chain variable region domain comprising the heavy chain HCDR3 of SEQ ID NO:5.
The Peptide or peptide complex according to any of the previous claims, said heavy chain variable region domain comprising the heavy chain CDRs of SEQ ID NO:3 (HCDR1), SEQ ID NO:4 (HCDR2), and SEQ ID NO:5 (HCDR3), or functionally active variants thereof.
The Peptide or peptide complex according to any one of the previous claims, said light chain variable region domain comprising the light chain LCDR3 of SEQ ID NO:8.
The Peptide or peptide complex according to any one of the previous claims, said light chain variable region domain comprising the light chain CDRs of SEQ ID NO:6 (LCDR1), SEQ ID NO:7 (LCDR2), and SEQ ID NO:8 (LCDR3), or functionally active variants thereof.
The Peptide or peptide complex according to any one of the previous claims, said heavy chain variable region (VH) domain having at least 90%, 95%, 97% or 99% sequence identity to the VH sequence of SEQ ID NO:
The Peptide or peptide complex according to any one of the previous claims, said light chain variable region (VL) domain having at least 90%, 95%, 97% or 99% sequence identity to the VL sequence of SEQ ID NO:
The Peptide or peptide complex according to any one of the previous claims, wherein said heavy chain variable region (VH) domain comprises one or more amino acid substitutions at positions selected from the group consisting of H5, H7, H11, H12, H17, H20, H38, H40, H43, H55, H61, H65, H66, H67, H76, H81, H82, H87, H91, H93, H112, H113 and H116.
The Peptide or peptide complex according to any one of the previous claims, wherein said light chain variable region (VL) domain comprises one or more amino acid substitutions at positions selected from the group consisting of L9, L12, L15, L22, L34, L46, L47, L80, L83, L85, L87, and L89.
The Peptide or peptide complex according to any one of the previous claims, said heavy chain variable region (VH) domain having at least 90%, 95%, 97% or 99% sequence identity to a VH sequence selected from the group consisting of SEQ ID NO:
The Peptide or peptide complex according to any one of the previous claims, said light chain variable region (VL) domain having at least 90%, 95%, 97% or 99% sequence identity to a VL sequence selected from the group consisting of SEQ ID NO:
The Peptide or peptide complex according to claim 24, said light chain variable region (VL) domain comprising a VL sequence selected from the group consisting of SEQ ID NO:
The Peptide or peptide complex according to any one of the previous claims, wherein said antibody or binding portion is a chimeric antibody or humanized antibody.
The Peptide or peptide complex according to any one of the previous claims, wherein the antigen binding portion is selected from the group consisting of a Fab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, a scFv, and a (scFv)2.
The Peptide or peptide complex according to any one of the previous claims, which is selected from the group consisting of a multispecific antibody, a dual specific antibody, a isotype antibody, a dual variable domain antibody and a bispecific antibody.
The Peptide or peptide complex according to any one of the previous claims, comprising a heavy chain immunoglobulin constant domain selected from the group consisting of:
The Peptide or peptide complex according to any one of the previous claims, comprising a human IgG4 constant domain.
The Peptide or peptide complex according to according to any of the previous claims, wherein the peptide or peptide complex comprises or consists of an isolated monoclonal antibody or antigen binding fragment thereof.
Dependencies are inferred from the claim text.